After his firm surveyed 30 neurologists treating at least ten Duchenne muscular dystrophy patients and at least five suspected/confirmed patients amenable to exon-51 skipping, Baird analyst Brian Skorney believes Sarepta Therapeutics' Exondys 51 is positioned for a strong launch. In a research note earlier today, Skorney said that most of the 30 doctors surveyed seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. The drug's consensus sales estimate for its first quarter on the market of $7.1M may be understating sales, Skorney wrote. The analyst continues to expect $11M of Exondys 51 sales in Q4. He has an Outperform rating on shares of Sarepta with a $102 price target. The stock is up 34c, or 1%, to $36.62 in morning trading.